970*90
768
468
mobile

AstraZeneca to acquire 9.8% stake in Innate Pharma

Franchise India Bureau
Franchise India Bureau Oct 24 2018 - 1 min read
AstraZeneca to acquire 9.8% stake in Innate Pharma
The acquisition will strengthen AstraZeneca's presence in the field of immuno-oncology.

AstraZeneca will acquire a newly-issued equity stake of 9.8% in smaller French peer Innate Pharma. The acquisition will strengthen AstraZeneca's presence in the field of immuno-oncology.

The British drugmaker will buy the stake via around 6.26 million new shares being issued to it at a price of 10 euros per share.

Pascal Soriot, Chief Executive Officer of AstraZeneca, said, "Our expanded collaboration with Innate Pharma enables us to further strengthen our leadership in immuno-oncology, and to explore the potential of next-generation immuno-oncology pathways, together with the world-class scientific team of Innate." 

Subscribe Newsletter
Submit your email address to receive the latest updates on news & host of opportunities
Entrepreneur Magazine

For hassle free instant subscription, just give your number and email id and our customer care agent will get in touch with you

or Click here to Subscribe Online